The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place.
Government is expanding prescription coverage for long-acting muscarinic antagonist (LAMAs) inhalers, used in the treatment of Chronic Obstructive Pulmonary Disease. The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place. This will ensure NLPDP beneficiaries have timely access to these inhalers for the treatment of their COPD.
Humber River and communities around it are under a flood watch
MNL concerned over changes to Multi-Year Capital Works Program and lack of consultation
It's Stop Sexual Exploitation Week, "It Happens Here; together we can create a safer community"
Seniors of Distinction Awards nominations accepted until Monday, May 11th
MHA says Corner Brook will lose $400K a year with changes to the Capital Works Program
